KRAS G12D

Assets acting on this target.

Class
KRAS G12D-directed
Pathway
RAS/MAPK signaling

KRAS is a small GTPase that functions as a molecular switch within the RAS/MAPK signaling pathway, cycling between an inactive, GDP-bound state and an active, GTP-bound state that transmits growth signals from cell-surface receptors to the nucleus. The G12D mutation, a substitution at codon 12, impairs the protein's intrinsic and GAP-assisted ability to hydrolyze GTP back to GDP, so the protein accumulates in its active conformation and drives continuous proliferative signaling independent of upstream cues. This mutation is common in pancreatic, colorectal, and other gastrointestinal cancers, and for decades KRAS was considered difficult to drug because its surface lacks deep pockets suitable for small-molecule binding. Newer inhibitors described as 'ON/OFF' are designed to engage KRAS G12D regardless of whether it is bound to GDP or GTP, in contrast to earlier mutant-selective RAS inhibitors that could only trap one nucleotide state. Complementary approaches include molecules that recruit cellular machinery to degrade the mutant protein entirely. Because RAS/MAPK signaling is also required for normal tissue maintenance, therapeutic strategies aim for mutant selectivity to reduce disruption of healthy cell signaling while shutting down the oncogenic drive.

By indication

Related mechanisms

KRAS G12D drugs compared

12 drugs, stage by indication
12 drugs acting on KRAS G12D: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
GFH375GenFleet Therapeutics, Verastem, Inc.small moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 2 in Pancreatic Ductal Adenocarcinoma
HRS-4642Jiangsu Hengrui PharmaceuticalsundisclosedPhase 3Phase 3 in Pancreatic Cancer
INCB161734Incytesmall moleculePhase 3Phase 3 in Pancreatic Ductal Adenocarcinoma
SetidegrasibAstellas Pharmasmall molecule (targeted protein degrader)Phase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Pancreatic Ductal Adenocarcinoma
ZoldonrasibRevolution Medicinessmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 3 in Pancreatic Cancer
ARV-806Arvinas Inc.small moleculePhase 1/2Not recorded
INV-8989Shenzhen Ionova Life Sciences Co., Ltd.small moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
QLC1101Qilu Pharmaceuticalsmall moleculePhase 1/2Phase 1 in Non-Small Cell Lung Cancer
TSN1611Tyligand Pharmaceuticals (Suzhou) Limitedsmall moleculePhase 1/2Not recorded
DebecarasibEli Lillysmall moleculePhase 1Not recorded
LT-010391Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.small moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer
RG6620RocheundisclosedStage not recordedNot recorded

← all mechanisms